OptionsHouse

Options Trading News

February 7, 2014  Fri 9:34 AM CT

CYTR: SEE CHART GET CHAIN FIND STRATEGIES
CytRx surged on promising cancer-drug data in December, and now traders are placing a vote of confidence in the name.

optionMONSTER's marker scanners detected the sale of 5,000 March 5 puts for $0.25. Volume was more than 7 times previous open interest, which indicates a new position was implemented.

The investor is now on the hook to buy shares for $5 if they're below that level on expiration six weeks from now. Above it, they'll keep the premium as profit. (See our Education section for more on how to make money selling puts.)

CYTR is up 1.66 percent to $6.75 in morning trading. It announced on Dec. 11 that a phase II trial showed its aldoxorubicin drug was twice as effective as traditional chemotherapy in the treatment of soft-tissue sarcoma. The stock more than tripled by late January but has been pulling back since.

Total option volume is almost 3 times greater than average so far today.
Share this article with your friends


OptionsHouse

Premium Services

Archived Webinar

Education & Strategy

Options Academy: At the Break

So far, my articles have taken you through a logical progression of option theory and fundamental concepts of options. As of yet, I have not mentioned a single strategy and for a good reason! The actual application of a strategy should come AFTER you learn about the option product itself.

View more education articles »